Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes
- PMID: 40300997
- DOI: 10.1093/ejendo/lvaf086
Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes
Abstract
Objective: Pituitary adenomas (PAs) are common neoplasms. Our current understanding of the molecular basis of PA formation is incomplete. Routine implementation of targeted genomics has enabled the discovery of rare, potentially clinically actionable events.
Methods: We used a cancer-focused gene panel to sequence a cohort of 171 PAs from patients who underwent surgery at Brigham and Women's Hospital from 2012 to 2020.
Results: We identified known genetic variants enriched in specific PA subtypes: GNAS (somatotroph) and USP8 (Cushing's disease). Total mutational burden did not vary across adenoma subtypes; most adenomas possessed a few non-recurrent mutations in various established oncogenes and tumor suppressors. In contrast, the burden of copy number alterations varied widely across adenoma subtypes and was associated with higher MIB1 labeling index. We identified frequent deletions spanning MEN1 in prolactinomas and silent corticotroph adenomas, and subtype-specific copy number changes including 16p, 16q alterations in somatotroph adenomas without GNAS mutations. Within the corticotroph lineage, adenomas leading to Cushing's disease had few copy number alterations while silent corticotroph adenomas had numerous.
Conclusions: This study highlights a role for individualized genetic events in PA formation and suggests that divergent patterns of genomic instability may facilitate tumorigenesis even within the same lineage. Taken together, we demonstrate how gene panels may illuminate novel biology in endocrine tumors.
Keywords: cancer genetics; copy number alterations; pituitary adenomas; targeted genomics.
© The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest: D.R.M. and A.M.L. are inventors on granted and pending patent applications owned by The Regents of the University of Michigan for compositions and methods of characterizing or treating cancer. The authors declare no other conflicts of interest that could be perceived as prejudicing the impartiality of the reported research.
Similar articles
-
Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.Acta Neuropathol Commun. 2020 Nov 10;8(1):190. doi: 10.1186/s40478-020-01067-5. Acta Neuropathol Commun. 2020. PMID: 33168091 Free PMC article.
-
USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.J Clin Endocrinol Metab. 2021 Mar 8;106(3):826-842. doi: 10.1210/clinem/dgaa853. J Clin Endocrinol Metab. 2021. PMID: 33221858
-
Novel Genetic Causes of Pituitary Adenomas.Clin Cancer Res. 2016 Oct 15;22(20):5030-5042. doi: 10.1158/1078-0432.CCR-16-0452. Clin Cancer Res. 2016. PMID: 27742789 Review.
-
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.J Clin Endocrinol Metab. 2015 Jul;100(7):E997-1004. doi: 10.1210/jc.2015-1453. Epub 2015 May 5. J Clin Endocrinol Metab. 2015. PMID: 25942478 Free PMC article.
-
Genomic Alterations in Sporadic Pituitary Tumors.Curr Neurol Neurosci Rep. 2018 Feb 2;18(1):4. doi: 10.1007/s11910-018-0811-0. Curr Neurol Neurosci Rep. 2018. PMID: 29396598 Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous